HAVCR2 and neoplasm: Based on the multiple mechanisms of TIM-3’s role in tumor and immunity, a variety of monoclonal antibodies against TIM-3 have entered the preclinical and clinical research stage in the last decade, including blockade of TIM-3 alone and combined blockade with other immune checkpoints, such as PD-1/PD-L1, CTLA-4, LAG-3, TIGIT, etc. (40, 41).